Navigation Links
Telik Announces Presentation and Webcast at 5th Annual OneMedForum Conference
Date:1/4/2012

PALO ALTO, Calif., Jan. 4, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate update at the 5th Annual OneMedForum Conference on Wednesday, January 11 at 12:00 p.m. Pacific time (3:00 p.m. Eastern time) in San Francisco.  A live and archived webcast of the presentation will be available on the Telik website, www.telik.com.  The archived broadcast of the presentation can be accessed for 30 days following the presentation.

About Telik
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Telik Announces Initiation of a Phase 2 Clinical Trial of Telintra® (Ezatiostat HCl) in Patients With Revlimid® Refractory or Resistant Deletion 5q Myelodysplastic Syndrome
2. Telik Announces Presentation and Webcast at 12th Annual BIO CEO & Investor Conference
3. Telik Announces Second Quarter 2009 Financial Results
4. Telik Reports Preclinical Results at AACR Annual Meeting
5. Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline
6. Telik Announces New TRAP Drug Discovery Agreement
7. Telik Announces Financial Results for 2008 Third Quarter
8. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
9. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
10. Telik Announces Receipt of Nasdaq Notice
11. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 Research and ... "Global Metabolomics Market 2014-2018" report to their ... Metabolomics or Metabonomics is the scientific ... become a new experimental technique that is being ... sciences. Metabolites are small molecules that are present ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
(Date:7/24/2014)... A novel combination of microscopy and data processing has ... National Laboratory an unprecedented look at the surface of ... properties. , The research team led by ORNL,s ... a perovskite manganite, a complex material that exhibits dramatic ... surface behavior could benefit researchers who are interested in ...
(Date:7/24/2014)... on sophisticated equipment, trained personnel, and detection dogs ... terrorist attacks. A revolutionary new electronic chip with ... job much easier. , The groundbreaking nanotechnology-inspired sensor, ... University ,s School of Chemistry and Center for ... company Tracense, picks up the scent of explosives ...
Breaking Biology Technology:Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2
... This week I spent time with a leading producer of ... The mission find out what aspects of the shopping ... sales representatives make a difference to how much the customer ... experience. , ,Customers were invited to the companys facilities ...
... and Chemicon International, Inc. announced today ... and apply Madison-based Promegas DNA-directed, RNA interference (ddRNAi) ... division of Serologicals Corporation, will have the right ... ddRNAi-based products and reagents for life science research. ...
... focused on the effects of outsourcing technology and offshore ... issue. Whatever the product, there is an effort to ... of this are hurting many aspects of Americans industrial ... making, whether you manufacture low- to high-tech products, maintain ...
Cached Biology Technology:Really Listening to Customers...AND Employees 2Really Listening to Customers...AND Employees 3Offshore outsourcing affects American workers 2Offshore outsourcing affects American workers 3
(Date:7/27/2014)... Barts Cancer Institute have found that targeting a molecule ... effective, according to research published in Nature ... of Queen Mary University of London, have found that ... body to repair itself after chemotherapy or radiotherapy, which ... removed FAK from blood vessels that grew in melanoma ...
(Date:7/25/2014)... burn scars on this false-color image from the Terra satellite ... year,s rash of wildfires in Eastern Russia. The burn ... green background. The wildfires have broken across the remote ... in this false-color image from the MODIS instrument, it ... fires that continue. Two recent image features noted below show ...
(Date:7/25/2014)... Birla, associate professor of biomedical engineering at the ... on tissue engineering and artificial organ development., "Introduction ... comprehensive guide to entering into the field of ... professor of biomedical engineering at UH, served as ... that while there are other published books on ...
Breaking Biology News(10 mins):New drug target can break down cancer's barrier against treatment 2University of Houston researcher publishes textbook on tissue engineering 2
... Americans are exposed to hundreds, if not thousands, of ... development and function of the brain, immune system, reproductive ... no public health law requires product testing of most ... That must change, UC Riverside professor Carl Cranor argues ...
... Rockville, Md., January 24, 2011 In collaboration ... and the Indian Pharmacopoeia Commission (IPC) will host the ... 17 and 18, 2011 in Hyderabad, India. The event ... bringing USP closer to its Indian counterpart in the ...
... The American Society for Microbiology (ASM) will host ... 6-9, 2011 at the Omni Shoreham Hotel in ... to bring together individuals who are carrying out research ... makers shaping the future biodefense research agenda, recognizing that ...
Cached Biology News:Legally poisoned 2Quality standards for biological, chemical drugs and public health are focus of India meeting 2
... polyclonal to BRF2 Immunogen Synthetic peptide: ... of Human BRF2. Reactivity / Specificity ... species. Background Information BRF2 is one ... III transcription factor complex required for transcription of ...
... Antibody - Red, 20X ... antibody at 20X concentration for use ... assays. Quality Assurance ... FarRed fluorescence polarization assays. ...
Kinase Buffer can be used to assay protein kinase activity...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Biology Products: